Akèy › Kansè tèt ak kou › Massachusetts
Etid klinik pou Kansè tèt ak kou nan Massachusetts
24 etid pou Kansè tèt ak kou ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0131, Boston
- Site#0101, Boston
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06788990The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06657222Toripalimab With Chemotherapy for Sinus Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06940180PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06239220A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT04545957PDT For Induction Therapy For Head And Neck Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07214987First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT07675967Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT06993844Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05726370A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 26, 2026 · NCT06256588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT03875716Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
- Brigham and Women's Hospital, Boston
Ap rekrite
Laj 18 a 85 · Tout sèks · Mizajou Feb 12, 2026 · NCT07405645Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jan 26, 2026 · NCT05553782SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542Comprehensive Outcomes for After Cancer Health
- Dana Farber Cancer Institute, Boston
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2024 · NCT05349227Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.